With the aim of obtaining more powerful inhibitors capable not only of modulating the immune response, but of promoting the differentiation and proliferation of neuronal cells, the synthesis of multi-target compounds for GSK3β and PDE7 was proposed for the treatment of neurodegenerative and demyelinating diseases [20]. The gene discussed is GSK3B; the disease is demyelinating disease.